Leon Chen - May 6, 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role: Director
Signature: /s/ Christine Ring, as Attorney-in-Fact for Leon Chen
Stock symbol: NRIX
Transactions as of: May 6, 2021
Transactions value $: $0
Form type: 4
Date filed: 5/24/2021, 07:48 PM
Next filing: Jun 14, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NRIX	Director Stock Option (right to buy)	Award	$0	+17.5K		$0.00	17.5K	May 6, 2021	Common Stock	17.5K	$27.38	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F2	The Reporting Person is a partner of The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and together with TCG II LP and Ponoi LP, the "Funds"), among other entities. Under the partnership agreements of the Funds, the Reporting Person is deemed to hold the stock option for the economic benefit of the Funds. The Funds may be deemed indirect beneficial owners of the stock option. The Reporting Person disclaims beneficial ownership of the stock option except to the extent of his pecuniary interest therein.

Content

The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

The Reporting Person is a partner of The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and together with TCG II LP and Ponoi LP, the "Funds"), among other entities. Under the partnership agreements of the Funds, the Reporting Person is deemed to hold the stock option for the economic benefit of the Funds. The Funds may be deemed indirect beneficial owners of the stock option. The Reporting Person disclaims beneficial ownership of the stock option except to the extent of his pecuniary interest therein.